Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EBIO Eleven Biotherapeutics (EBIO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Eleven Biotherapeutics Stock (NASDAQ:EBIO) 30 days 90 days 365 days Advanced Chart Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Eleven Biotherapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume15.58 million shsAverage Volume2.86 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.Read More… Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Receive EBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eleven Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address EBIO Stock News HeadlinesAtara Biotherapeutics Inc.September 4, 2024 | wsj.comFlagship Ventures Fund IV-Rx, L.P.'s Net WorthSeptember 1, 2024 | benzinga.comBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. November 21, 2024 | WealthPress (Ad)7-Eleven Australia’s family owners sell for $1.71bDecember 2, 2023 | afr.comEleven councillors quit Labour Party as Keir Starmer refuses to back Gaza ceasefireNovember 11, 2023 | mirror.co.ukCalifornia mayor criticizes Prop 47 after 7-Eleven Sikh employees beat alleged thiefAugust 16, 2023 | foxnews.comFree Slurpees? Yes, here's how to get one today and Tuesday, 7-Eleven's 96th birthdayJuly 31, 2023 | usatoday.comChicago police close in on 7-Eleven robbery suspects in LawndaleApril 9, 2023 | cbsnews.comSee More Headlines EBIO Stock Analysis - Frequently Asked Questions How were Eleven Biotherapeutics' earnings last quarter? Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) released its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. What other stocks do shareholders of Eleven Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eleven Biotherapeutics investors own include Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Immunomedics (IMMU), SELLAS Life Sciences Group (SLS), Sesen Bio (SESN), TransEnterix (TRXDW) and Dynavax Technologies (DVAX). Company Calendar Last Earnings5/15/2018Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EBIO CUSIPN/A CIK1485003 Webwww.elevenbio.com Phone(617) 444-8550FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:EBIO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eleven Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eleven Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EBIO Stock Alerts